

Final Height Outcome after Three Years of Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Short Adolescents with Relatively Early Puberty

Sandy A. van Gool, Gerdine A. Kamp, Hanneke Visser-van Balen, Dick Mul, Johan J. J. Waelkens, Maarten Jansen, Liesbeth Verhoeven-Wind, Henriëtte A. Delemarre-van de Waal, Sabine M. P. F. de Muinck Keizer-Schrama, Geraline Leusink, Jan C. Roos, and Jan M. Wit

Department of Pediatrics (S.A.v.G., J.M.W.), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands; Tergooi Hospital (G.A.K.), 1250 CA Blaricum, The Netherlands; Department of Developmental Psychology (H.V.-v.B.), Utrecht University, 3508 TA Utrecht, The Netherlands; Subdivision Endocrinology (D.M., S.M.P.F.d.M.K.-S.), Erasmus University Medical Center / Sophia Children's Hospital, 3015 GJ Rotterdam, The Netherlands; Catharina Hospital (J.J.J.W.), 5623 EJ Eindhoven, The Netherlands; University Medical Center Utrecht / Wilhelmina Children's Hospital (M.J., L.V.-W., H.V.-v.B.), 3508 AB Utrecht, The Netherlands; Departments of Pediatrics (H.A.D.-v.d.W.) and Radiology (J.C.R.), VU University Medical Center, 1007 MB Amsterdam, The Netherlands; and Diagnostic Center Eindhoven (G.L.), 5611 NE Eindhoven, The Netherlands

Objective: Our objective was to assess final height (FH) and adverse effects of combined GH and GnRH agonist (GnRHa) treatment in short adolescents born small for gestational age or with normal birth size (idiopathic short stature).

Design and Patients: Thirty-two adolescents with Tanner stage 2–3, age and bone age (BA) less than 12 yr for girls or less than 13 yr for boys, height SD score (SDS) less than -2.0 SDS or between -1.0 and -2.0 SDS plus a predicted adult height (PAH₀) less than -2.0 SDS were randomly allocated to receive GH plus GnRHa ($n = 17$) or no treatment ($n = 15$) for 3 yr. FH was assessed at the age of 18 yr or older in girls or 19 yr or older in boys.

Results: FH was not different between treatment and control groups. Treated children had a larger height gain (FH – PAH₀) than controls:

4.4 (4.9) and -0.5 (6.4) cm, respectively ($P < 0.05$). FH was higher than PAH₀ in 76 and 60% of treated and control subjects, respectively. During follow-up, 50% of the predicted height gain at treatment withdrawal was lost, resulting in a mean gain of 4.9 cm (range, -4.0 to 12.3 cm) compared with controls. Treatment did not affect body mass index or hip bone mineral density. Mean lumbar spine bone mineral density and bone mineral apparent density tended to be lower in treated boys, albeit statistically not significant.

Conclusion: Given the expensive and intensive treatment regimen, its modest height gain results, and the possible adverse effect on peak bone mineralization in males, GH plus GnRHa cannot be considered routine treatment for children with idiopathic short stature or persistent short stature after being born small for gestational age. (*J Clin Endocrinol Metab* 92: 1402–1408, 2007)

SHORT CHILDREN WITH a relatively early onset of puberty often attain a poor final height (FH) due to premature growth acceleration and epiphyseal fusion induced by the pubertal rise in sex steroid levels (1). GH treatment increases FH in children with idiopathic short stature (ISS) or a persistent short stature after being born small for gestational age (SGA), particularly when initiated in early childhood (2). The effect of GH therapy is dose dependent, with lower dosages being less efficacious (3, 4), whereas too high doses may accelerate growth velocity and stimulate a rapid progression through puberty, possibly limiting FH gain (5).

Once puberty has started, GH treatment may limit FH gain, because by that time the process of epiphyseal maturation has already been set in motion (6).

An alternative for GH treatment is to delay or halt pubertal onset with GnRH agonists (GnRHa). However, in many children, GnRHa therapy concomitantly decreases growth velocity to values below the normal prepubertal pace, which may at least in part result from accelerated growth plate senescence induced by previous estrogen exposure (7).

Combined GH and GnRHa treatment in adolescents with short stature has been analyzed in a few studies with limited numbers of patients and conflicting results. None of these were randomized controlled trials (RCT), and FH results are scarce. Height gain defined as the difference between FH and baseline predicted adult height (PAH₀) was 1.0–10.0 cm (8–13). Treatment response was usually analyzed by comparison with a GH-treated group (12, 14) or a not randomly assigned, untreated control group (9, 15) or no control group at all (8). Moreover, most of the trials focused on girls only and excluded children with a persistent short stature after being born SGA.

In 2001, we reported 3-yr results of the first RCT investigating GH plus GnRHa (GH + GnRHa) treatment in short,

First Published Online February 6, 2007

Abbreviations: BA, Bone age; BMAD, bone mineral apparent density; BMD, bone mineral density; BMI, body mass index; CA, chronological age; CI, confidence interval; DXA, dual-energy x-ray absorptiometry; FH, final height; GnRHa, GnRH agonist; ISS, idiopathic short stature; PAH_{0/3y}, predicted adult height at baseline/at discontinuation of treatment; RCT, randomized controlled clinical trial; SDS, SD score; SGA, small for gestational age; TH, target height.

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

early pubertal adolescents with ISS or SGA. We concluded that 3 yr of GnRHa treatment was effective in suppressing puberty, whereas growth velocity was preserved due to addition of GH, resulting in a significant gain in PAH without demonstrable side effects (16). Assessment of the motives of adolescents and their parents to participate in this trial and psychosocial functioning of the participants during treatment were described recently (17, 18). Psychosocial functioning in young adulthood will be described elsewhere (Visser-van Balen, H., submitted for publication). Here we report FH data and analyze possible adverse effects of treatment on bone mineral density (BMD), bone mineral apparent density (BMAD), and body mass index (BMI).

Patients and Methods

Patients

This report includes FH results from 32 of 40 adolescents with short stature that originally enrolled in a multicenter study in The Netherlands in 1993–1996. Inclusion criteria were chronological age (CA) and bone age (BA) less than 12 yr (girls) or less than 13 yr (boys); pubertal stage of G2–3 (boys) or B2–3 (girls); height at baseline (H_0) less than -2.0 SDS for Dutch references (19) or between -1.0 and -2.0 sd score (SDS) with PAH_0 less than -2.0 SDS, according to Bayley and Pinneau, (20); maximum serum GH level more than $10 \mu\text{g/liter}$ ($1 \text{ mg} = 2 \text{ IU}$, using World Health Organization (WHO) International Reference Preparation 66/217 as standard) after provocation (exercise, arginine, clonidine, L-dopa, or glucagon), and a normal sitting height/subischial leg length ratio (between P3 and P97) (21). Screening blood tests and urinalysis were normal. No organic cause of growth failure, primary bone disease, chronic illness, or dysmorphic syndrome was present. During the trial phase, fasting glucose and insulin levels remained within the normal range in all children. Markers for bone formation (osteocalcin, alkaline phosphatase, procollagen type IC propeptide, and procollagen type III N propeptide) were not different between treatment and control groups. Details of the subjects and data obtained after withdrawal of treatment were reported previously (16).

The protocol was approved by medical ethical review boards at the four participating centers (Amsterdam, Utrecht, Eindhoven, and Rotterdam). Before conducting any study-related procedure, written informed consent was obtained from parents and, when appropriate, also from the participants. This clinical trial was registered in the metaRegister of Controlled Trials (ISRCTN82161629) of the Current Controlled Trials Ltd.

Study design

Forty patients were randomly allocated to receive combined treatment with GH + GnRHa or no treatment for a period of 3 yr (Fig. 1). GH (Genotropin; Pharmacia, Uppsala, Sweden; now Pfizer, New York, NY) was given in a dose of 1.33 mg ($4 \text{ IU}/\text{m}^2 \cdot \text{d}$ sc, equivalent to 0.05 mg/kg body weight·day. A 3.75-mg 1-month depot preparation of GnRHa was administered im [triptorelin (Decapeptyl) Ferring, Malmö, Sweden; after withdrawal by Ferring in 1998, triptorelin from Ipsen, Paris, France, was used]. This corresponded to a mean triptorelin dose of $125 \mu\text{g/kg}$ at start of treatment and $67 \mu\text{g/kg}$ at discontinuation of treatment.

Randomization was performed separately in children born SGA, defined as birth length less than -2.0 SDS (22). Directly after randomization, four patients (two from each group) refused to start the intervention they were randomly allocated to receive and dropped out. Additionally, two patients dropped out from the control group due to a lack of motivation for visiting the outpatient clinic during the trial phase, and another two (one in each group) could not be traced and were lost to follow-up.

Adolescents were considered to have attained FH if treatment withdrawal was at least 3 yr before evaluation and CA was greater than or equal to 18 yr (girls) or 19 yr (boys). FH, being the average of four measurements made by a single observer using a Harpenden stadiometer, was determined at an outpatient clinic visit or at a house visit.


BMD

BMD of the lumbar vertebrae and hip were measured by dual-energy x-ray absorptiometry (DXA) at the moment of FH analysis. DXA scans were performed at the Department of Radiology of the VU University Medical Center in Amsterdam or at the Diagnostic Center Eindhoven using a Hologic Delphi 4500A or a Hologic Delphi W-type 70991 (Hologic, Waltham, MA), respectively. Cross-calibration with phantoms demonstrated that the DXA machines were comparable, and data from both centers were pooled. Each machine was calibrated using the manufacturer's daily quality control protocol. Z-scores were calculated, using hip reference values based on the National Health and Nutrition Examination Survey from 1988–1991 (NHANES) (23) and Hologic reference values for lumbar spine (L1–L4). To correct for bone size, DXA-derived data were used to calculate lumbar spine BMAD (24). BMAD Z-scores could not be calculated due to the lack of appropriate reference values.

Outcome parameters

Four outcome parameters were used to evaluate response to treatment: 1) FH (SDS); 2) FH minus baseline height (H_0) (SDS); 3) FH minus

FIG. 1. Trial design.



PAH₀ (cm) according to Bayley and Pinneau (20); and 4) FH minus target height (TH) (cm). FH minus PAH₃ (PAH at discontinuation of treatment) was also calculated, to show the difference between final outcome and height prediction at discontinuation of treatment. All SDS were based on Dutch references (19). For calculation of FH SDS, the age of each patient was set at 21 yr, enabling comparison of FH with height distribution in the normal adult population. For three patients, a BA radiograph at baseline was not available, and BA determination closest to this time point was used and transformed to BA_{baseline}, as follows: BA_{baseline} = (BA_{visit}/CA_{visit}) × age_{baseline}. TH was calculated as midparental height plus or minus 6 cm (for boys and girls, respectively), plus 3 cm to correct for the average secular trend in The Netherlands (25). One patient's TH could not be calculated, because of adoption from a foreign country and absence of height data of his biological parents.

The following outcome parameters were used to analyze possible effects of GH + GnRHa treatment on bone mineralization and body weight: 1) lumbar spine BMD (SDS) and BMAD (g/cm³); 2) hip BMD (SDS); and 3) BMI (SDS).

Statistical analysis

The study was designed to compare the effects of GH + GnRHa treatment with those of no treatment on FH. Statistical analyses were performed using the statistical package SPSS, version 11.0.1 (SPSS, Chicago, IL). Results are expressed as mean (sd). Comparisons among treatment and control groups were made using Student's unpaired *t* tests. Possible interactions between GH + GnRHa treatment and the baseline predictors gender, diagnostic subgroup, age at baseline (age₀), height at baseline (H₀SDS), and BA delay (CA – BA) were analyzed by means of linear regression analysis using ANOVA. The significance level was set at 0.05.

Results

A complete case analysis was carried out for the remaining 32 of 40 originally included patients (80%). One patient from the GH + GnRHa group discontinued treatment after 2 yr due to a lack of motivation, but her near-FH 2 yr after termination of treatment was included in the evaluation. Anthropometric data were not statistically different between treatment and control groups at baseline, but PAH and TH happened to be about 3 cm lower in the treatment group. During the trial phase, clinical (Tanner stage) and biochemical (serum estradiol and testosterone levels) evaluation demonstrated that pubertal development was effectively arrested in the GH + GnRHa group, whereas puberty progressed in the control group (16). After withdrawal of therapy, pubertal development immediately resumed, with most children from the GH + GnRHa group reaching Tanner V development within 1–2 yr and most girls reaching menarche within 1 yr. All participants were sexually mature at final analysis.

There was a significant gain in PAH of 9.3 cm after 3 yr of GH + GnRHa treatment, compared with 1.2 cm gain in the control group (Fig. 2). There was no significantly different pattern between the two diagnostic subgroups and genders in changes in height parameters.

Effect on growth

Patient characteristics at start, after treatment discontinuation, and at the moment of FH analysis are listed in Table 1. FH data were collected at a mean age of 19.9 (1.8) and 20.9 (1.0) yr in girls and boys, respectively. The mean treatment period was 3.0 yr (range, 2.8–3.3 yr). The mean period elapsed between treatment discontinuation and final analysis was 5.7 yr (range, 3.6–8.7 yr).




FIG. 2. Height gain (cm) compared with PAH at baseline (FH – PAH₀) and after discontinuation of treatment (FH – PAH₃). *, *P* < 0.1; **, *P* < 0.05; ***, *P* < 0.001.

FH SDS [–2.0 (1.0) *vs.* –2.3 (0.6)] and height gain compared with H₀SDS [0.5 (0.9) *vs.* 0.3 (0.6)] were not significantly different between treated and control subjects. In the GH + GnRHa group, 53% reached a FH greater than –2.0 SDS, compared with 33% of control patients (difference not statistically significant). The treated subjects attained a FH closer to TH than controls [–6.0 (7.2) *vs.* –11.2 (5.7) cm; *P* < 0.05], but mean FH of treated subjects was still significantly lower than TH (*P* < 0.01).

Height gain (FH – PAH₀) was 4.4 (4.9) in the treatment and –0.5 (6.4) cm in the control group (Fig. 2B). Of the predicted 9.3 cm gain in PAH (PAH₃ – PAH₀), approximately 50% was lost during follow-up (Fig. 2), resulting in a net gain of 4.9 cm in the treatment group, compared with controls. Seventy-six percent of the GH + GnRHa-treated children and 60% of the controls had a FH greater than predicted at baseline.

Height gain was similar in both genders, but there was a difference in the accuracy of the height prediction method between genders. Untreated boys attained a FH 5.5 (4.1) cm lower than predicted at baseline, whereas untreated girls became 1.9 (6.0) cm taller. Treated girls had a FH significantly closer to TH than controls (*P* < 0.05), whereas no significant difference existed between treated and untreated boys.

Linear regression analysis of predictors for growth response

Gender was a predictor for the treatment effect [(GH + GnRHa) × gender] expressed in FH – TH, with girls showing a better response than boys [regression coefficient B = 10.7; confidence interval (CI) = 1.3–20.2; *P* < 0.05; graph not shown]. Age at baseline showed a trend toward a positive interaction with treatment effect [(GH + GnRHa) × age₀] in the outcome parameters FH SDS – H₀SDS (B = 0.7; CI = –0.01–1.5; *P* < 0.1), and FH SDS – PAH₀ SDS (B = 0.8; CI = –0.1–1.7; *P* < 0.1). Baseline height and diagnostic subgroup were not significant predictors for treatment effect in any of the outcome parameters.

Side effects

Lumbar spine and hip BMD were determined in 21 patients (69%), 15 treated and six control subjects; the others could not be motivated. There was no apparent difference in lumbar spine and hip BMD SDS between treated and untreated children (Fig. 3, A and C). Lumbar spine BMD SDS was markedly lower in the six treated boys [–2.5 (1.0) SDS]

TABLE 1. Summary of initial and outcome variables

	All			Boys			Girls		
	GH+GnRHa (n = 17)	Control (n = 15)	Treatment <i>vs.</i> control	GH+GnRHa (n = 6)	Control (n = 5)	Treatment <i>vs.</i> control	GH+GnRHa (n = 11)	Control (n = 10)	Treatment <i>vs.</i> control
Boys/girls	6/11	5/10							
SGA/ISS	6/11	5/10		2/4	2/3		4/7	3/7	
At start of treatment									
Age ₀ (yr)	11.6 (0.7)	11.8 (0.7)	NS	11.9 (0.8)	12.5 (0.6)	NS	11.4 (0.6)	11.5 (0.5)	NS
BA delay (yr)	0.7 (1.0)	1.0 (0.7)	NS	1.1 (1.0)	1.2 (0.7)	NS	0.5 (0.9)	0.9 (0.8)	NS
H ₀ (cm)	135.4 (4.5)	136.1 (4.5)	NS	133.1 (3.8)	138.4 (5.8)	NS	136.7 (4.5)	134.9 (3.4)	NS
H ₀ (SDS)	-2.4 (0.5)	-2.5 (0.5)	NS	-2.7 (0.4)	-2.5 (0.5)	NS	-2.3 (0.5)	-2.6 (0.5)	NS
PAH ₀ (cm)	157.4 (8.3)	160.0 (10.1)	NS	166.7 (4.9)	170.7 (8.7)	NS	152.4 (5.6)	154.7 (5.6)	NS
PAH ₀ (SDS)	-2.7 (0.7)	-2.3 (1.0)	NS	-2.5 (0.7)	-1.9 (1.2)	NS	-2.8 (0.7)	-2.5 (0.9)	NS
TH (cm)	167.4 (10.0)	170.7 (5.8)	NS	176.9 (9.6)	174.9 (4.1)	NS	163.1 (6.9)	168.6 (5.5)	NS
BMI ₀ (SDS)	-0.6 (0.9)	-0.5 (1.0)	NS	-0.7 (1.4)	0.0 (0.5)	NS	-0.6 (0.5)	-0.8 (1.0)	NS
Discontinuation of treatment									
Age ₃ (yr)	14.9 (0.7)	14.6 (0.7)	NS	15.4 (0.6)	14.9 (0.8)	NS	14.6 (0.5)	14.4 (0.6)	NS
H ₃ (cm)	154.6 (5.5)	152.9 (5.4)	NS	159.7 (6.7)	152.1 (5.9)	NS	152.1 (2.5)	153.3 (5.3)	NS
H ₃ (SDS)	-2.1 (0.8)	-2.2 (0.4)	NS	-2.7 (0.7)	-2.2 (0.6)	NS	-1.8 (0.7)	-2.1 (0.3)	NS
PAH ₃ (cm)	166.7 (8.1)	161.3 (9.5)	<i>P</i> < 0.1	174.0 (6.9)	169.3 (12.3)	NS	162.8 (5.8)	157.3 (4.6)	<i>P</i> < 0.05
PAH ₃ (SDS)	-1.3 (0.9)	-2.1 (1.1)	<i>P</i> < 0.05	-1.4 (1.0)	-2.1 (1.7)	NS	-1.2 (0.9)	-2.1 (0.7)	<i>P</i> < 0.05
BMI ₃ (SDS)	-0.3 (1.0)	-0.4 (1.1)	NS	0.0 (1.1)	-0.6 (1.8)	NS	-0.5 (1.1)	-0.2 (0.4)	NS
At FH									
Age _f (yr)	20.3 (1.6)	20.2 (1.8)	NS	20.4 (0.8)	21.5 (1.0)	NS	20.2 (1.9)	19.5 (1.7)	NS
FH (cm)	161.8 (6.3)	159.5 (5.7)	NS	165.6 (5.7)	165.2 (5.1)	NS	159.8 (5.8)	156.6 (3.3)	NS
FH (SDS)	-2.0 (1.0)	-2.3 (0.6)	NS	-2.6 (0.8)	-2.7 (0.7)	NS	-1.7 (0.9)	-2.2 (0.5)	NS
FH - H ₀ (SDS)	0.5 (0.9)	0.3 (0.6)	NS	0.2 (0.7)	-0.2 (0.4)	NS	0.6 (1.0)	0.4 (0.6)	NS
FH - PAH ₀ (cm)	4.4 (4.9)	-0.5 (6.4)	<i>P</i> < 0.05	-1.0 (2.4)	-5.5 (4.1)	<i>P</i> < 0.1	7.4 (3.0)	1.9 (6.0)	<i>P</i> < 0.05
FH - PAH ₃ (cm)	-4.9 (3.8)	-1.8 (4.9)	<i>P</i> < 0.1	-8.3 (3.1)	-4.0 (7.4)	NS	-3.0 (2.8)	-0.7 (3.0)	<i>P</i> < 0.1
FH - TH (cm)	-6.0 (7.2)	-11.2 (5.7)	<i>P</i> < 0.05	-11.8 (6.5)	-9.7 (6.9)	NS	-3.3 (5.9)	-12.0 (5.3)	<i>P</i> < 0.05
BMI _f (SDS)	0.0 (0.8)	0.1 (0.9)	NS	-0.4 (0.9)	0.3 (1.2)	NS	-0.3 (0.5)	0.0 (0.7)	NS

Results are presented as mean (SD). NS, No significant difference.

than in the two controls [-1.1 (0.3) SDS] who consented to undergo this diagnostic procedure (*P* = 0.1; CI = -0.5–3.3). This difference was statistically not significant due to the small sample size of the control group (*n* = 2). Lumbar spine BMAD showed a similar, albeit less prominent pattern (Fig. 3B). BMI SDS remained unchanged during and after GH + GnRHa treatment in boys and girls.

Discussion

We report FH results of the first RCT of combined GH + GnRHa treatment in short boys and girls that includes an untreated control group. Treatment resulted in a modest increase of approximately 5 cm compared with controls, as documented by the difference between obtained adult height and initial PAH and TH. The reason that the differences in final height SDS as such and the change in height SDS were not statistically significant is probably that the PAH at start, as well as the TH, of the children randomly allocated to the treatment group happened to be approximately 3 cm lower than in controls.

Two previously published studies employed untreated controls as reference group. Saggese *et al.* (26) found an increase in PAH of 6.1 cm after 2 yr of GH + GnRHa in seven ISS girls compared with controls. In contrast, Lanes and Gunczler (9) found no improvement in PAH or FH after 2.5 yr of treatment in 10 short boys and girls. Other studies with different experimental designs showed similarly contrasting results on growth, varying from no effect on FH or PAH gain in girls with familial short stature (8) and in ISS boys and girls (14) to 10.5 cm gain in PAH and 10 cm height gain (FH - PAH₀) in ISS girls (12). These studies and ours cannot easily be compared because of differences in experimental design.

GH + GnRHa trials in short adopted girls showed an increased PAH, FH - PAH₀, and FH compared with GnRHa-treated controls (10, 13). Mul *et al.* (10) suggested that the relevance of their results in adopted girls might be extrapolated to girls born SGA and those with ISS. Indeed, in our trial, we found significantly increased PAH, height gain, and FH compared with TH in the treated girls.

Approximately 50% of the apparent gain in PAH during treatment was lost during follow-up. Initial height prediction overestimated FH in untreated boys, which has also been described by others (27). Height gain in terms of FH - PAH₀ is similar in both genders, although the accuracy of height prediction depends on gender. Untreated boys attain a FH considerably lower than predicted at baseline, whereas girls become slightly taller. Prediction at discontinuation of treatment overestimated FH, regardless of gender. A longer duration of combined therapy might further increase height gain but would delay puberty even longer up to an age that would far exceed the normal range. This might cause adverse effects on psychological and bone parameters. However, prolonging GH treatment after discontinuation of combined treatment until FH may be a way to fulfill part of the height gain predicted in PAH₃.

Gender did not influence the response to GH + GnRHa in three of four outcome parameters. Only for FH - TH was a better response to treatment seen in girls. Previously published studies on GH + GnRHa treatment were usually conducted in short girls only, except a few small trials including both genders (9, 14). The inclusion of boys in our trial might explain a somewhat lower overall response to treatment compared with other studies on GH + GnRHa treatment in short girls. The predictive value of gender on height outcome




FIG. 3. Effect of GH plus GnRHa treatment on lumbar spine BMD expressed as Z-score (A), lumbar spine BMAD expressed in g/cm^3 (B), and total hip expressed as Z-score (C). Error bars represent SD.

is limited in this study, because an effect was found in only one outcome measure (FH – TH).

We included an SGA subgroup, even though this category of patients was excluded from the 1996 consensus definition of ISS (28) and from most of the previously published studies. In our opinion, the distinction between ISS and idiopathic SGA is arbitrary because of varying definitions and reference values for length and weight for gestational age. In the ISS consensus, SGA was defined as a birth weight and/or length less than -2.0 SDS for gestational age. This definition implies that a child with a birth weight in the lower normal range may be categorized as ISS in case of an unknown birth length and as SGA if birth length would be recorded as less than -2.0 SDS. Moreover, the Gaussian distribution of birth weight and length in ISS is shifted to the left by 1 SDS (29), suggesting that persistent short stature born SGA and ISS are not separate entities. SGA and ISS children in our study had a similar response to treatment, demonstrating that diagnostic subgroup did not interact with the treatment effect. Similarly, Crowe *et al.* (30) found no difference in response to GH treatment between SGA or ISS groups. However, patient numbers in our subgroups were small, and larger sample numbers are required to analyze responses to definitely confirm or reject our hypothesis that SGA and ISS children respond similarly to combined GH + GnRHa treatment.

Apart from beneficial effects on height gain, GH + GnRHa treatment may also have adverse effects. Palmert *et al.* (31) found an elevated BMI in GnRHa-treated girls with central precocious puberty. We did not find an increased BMI, either directly after discontinuation of treatment (16) or at FH analysis. The stimulatory effect of GnRHa on fat mass induction

may have been counterbalanced by an adverse effect of GH in the treated children. The elevated BMI in GnRHa-treated girls from the American trial was possibly associated with precocious puberty itself rather than with the treatment.

Another relevant possible side effect of GnRHa treatment was described by Yanovski *et al.* (32), who found a significantly decreased lumbar spine BMD after 4 yr of GnRHa treatment, with or without GH, of children with short stature based on various etiologies. A similar result was reported after 3.4 yr of GnRHa treatment in girls with ISS (33). In GnRHa-treated children with central precocious puberty, lumbar spine BMD was significantly decreased during treatment (34) but restored to normal values several years after withdrawal of treatment (33, 34), suggesting that GnRHa therapy did not impair peak bone mass in this subcategory of patients. In contrast, Finkelstein *et al.* (35) demonstrated that adult men with a history of delayed puberty had a decreased radial and spinal BMD, suggesting that the timing of puberty is an important determinant of peak bone density in men. BMD achieved during young adulthood might be a major determinant of bone density and a predictor for the risk of osteoporotic fractures in later life.

In our study, there was no apparent difference between treatment and control groups in lumbar spine and hip BMD measured at least 3.5 yr after termination of treatment. However, the six treated boys had a lower lumbar spine BMD and BMAD than the two untreated boys, albeit statistically not significant. A meta-analysis by Marshall *et al.* (36) demonstrated that with each 1 SDS decrease in lumbar spine BMD, fracture risk increased 2.3-fold. Therefore, we believe that there is sufficient reason to be cautious when considering GH + GnRHa treatment in boys. On the other hand, it has been shown that after interruption of skeletal development in childhood, there is still potential for catch-up in BMD, even going into the third decade of life (37, 38). Taking this into account, it remains to be seen whether the low lumbar spine BMD in treated boys has clinical repercussions and whether it will restore to normal values.

In girls, there was no difference in lumbar spine and hip BMD between treated and control groups. This may be explained by an immediate rise in estrogen to high levels after treatment withdrawal in girls, favoring bone mineralization. In boys, the posttreatment rise in estrogen levels may be slower and reach a lower maximum, resulting in a later and possibly lesser stimulation of bone mineralization.

Apart from these clinical issues, psychosocial issues should also be taken into account. Analyses of psychosocial functioning during treatment tentatively suggested adverse psychological consequences for the treated adolescents on self-perceived competence of scholastic and athletic ability and trait anxiety (17). Parents reported some behavioral problems in their children before treatment (18) but did not report changes during treatment. Psychosocial outcome after attaining final adult height was one of the final evaluation criteria of this trial, and so far no differences have been observed between treatment and control groups in social circumstances, height-related psychosocial stressors, perceived competence, and psychological distress in young adulthood (Visser-van Balen, H., submitted for publication).

We conclude that 3 yr of GH + GnRHa treatment has a

positive but modest effect of 4.9 cm on final height in short, early pubertal children with ISS or a persistent short stature born SGA, compared with untreated controls. The costs of long-term treatment with GH + GnRHa of short but otherwise healthy patients with extremely expensive drugs that require parenteral administration and regular clinic visits and may have an adverse effect on peak bone mineralization, particularly in males, overshadows the modest benefit of 4.9 cm height gain. We therefore do not recommend this treatment regimen in general. However, treatment may be felt justified in individual patients, particularly girls, with an extremely low adult height prediction, an early pubertal onset, and considerable psychosocial problems.

Acknowledgments

We thank Dr. Oostdijk for contributing to the design of the trial. We express our gratitude to Prof. Dr. Manoliu of the Department of Radiology and Mr. Burcksen of the Department of Nuclear Medicine of the VU University Medical Center, Mr. van der Horst of the Diagnostic Center Eindhoven, and Mrs. Clemens of the Catharina Hospital Eindhoven for facilitating and supervising DXA scanning in our patients. The authors are grateful to Pfizer (New York, NY) for their continuing supply of recombinant hGH and to Ferring (Hoofddorp, The Netherlands) for the Decapeptyl supply. We greatly appreciate the financial support of both Pfizer and Ferring for this study. We thank all patients and their parents for participating in this trial.

Received October 17, 2006. Accepted January 29, 2007.

Address all correspondence and requests for reprints to: Dr. S. A. van Gool, Leiden University Medical Center, Department of Pediatrics, J6-S, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail: s.van_gool@lumc.nl.

This work was supported by Ferring (Hoofddorp, The Netherlands) and Pfizer (New York, NY) and by a grant from ZonMW, The Netherlands Organization for Health Research and Development (to S.A.v.G.).

Part of this work was presented as a poster at the 7th Joint Meeting of European Society for Paediatric Endocrinology/Lawson Wilkins Paediatric Endocrine Society, Lyon, France, September 2005.

Author Disclosure Summary: S.A.v.G., G.A.K., H.V.-v.B., D.M., J.J.J.W., M.J., L.V.-W., H.A.D.-v.d.W., G.L., and J.C.R. have nothing to declare. S.M.P.F.d.M.K.-S. has been paid lecture fees by Novo Nordisk and Pfizer. J.M.W. has received consulting fees and lecture fees from Pfizer, Lilly, and Ipsen.

References

- Cutler Jr GB 1997 The role of estrogen in bone growth and maturation during childhood and adolescence. *J Steroid Biochem Mol Biol* 61:141–144
- Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cutler L 2002 Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. *Arch Pediatr Adolesc Med* 156:230–240
- Wit JM, Rekers-Mombarg LT 2002 Final height gain by GH therapy in children with idiopathic short stature is dose dependent. *J Clin Endocrinol Metab* 87:604–611
- Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, Gill A, Chaussain JL, Frisch H, Yturriaga R, Attanasio AF 2005 Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. *J Pediatr* 146:45–53
- Kamp GA, Waelkens JJ, de Muinck Keizer-Schrama SM, Delemarre-van de Waal HA, Verhoeven-Wind L, Zwinderman AH, Wit JM 2002 High dose growth hormone treatment induces acceleration of skeletal maturation and an earlier onset of puberty in children with idiopathic short stature. *Arch Dis Child* 87:215–220
- Nilsson O, Baron J 2004 Fundamental limits on longitudinal bone growth: growth plate senescence and epiphyseal fusion. *Trends Endocrinol Metab* 15:370–374
- Weise M, Flor A, Barnes KM, Cutler Jr GB, Baron J 2004 Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. *J Clin Endocrinol Metab* 89:103–107
- Balducci R, Toscano V, Mangiantini A, Municchi G, Vaccaro F, Picone S, Di Rito A, Boscherini B 1995 Adult height in short normal adolescent girls treated with gonadotropin-releasing hormone analog and growth hormone. *J Clin Endocrinol Metab* 80:3596–3600
- Lanes R, Gunczler P 1998 Final height after combined growth hormone and gonadotropin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. *Clin Endocrinol (Oxf)* 49:197–202
- Mul D, Oostdijk W, Waelkens JJ, Drop SL 2005 Final height after treatment of early puberty in short adopted girls with gonadotropin releasing hormone agonist with or without growth hormone. *Clin Endocrinol (Oxf)* 63:185–190
- Pasquino AM, Pucarelli I, Segni M, Matruncola M, Cerroni F 1999 Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. *J Clin Endocrinol Metab* 84:449–452
- Pasquino AM, Pucarelli I, Roggini M, Segni M 2000 Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. *J Clin Endocrinol Metab* 85:619–622
- Tuvemo T, Jonsson B, Gustafsson J, Albertsson-Wikland K, Aronson AS, Hager A, Ivarson S, Kristrom B, Marcus C, Nilsson KO, Westgren U, Westphal O, Aman J, Proos LA 2004 Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty. *Acta Paediatr* 93:1456–1462
- Job JC, Toublanc JE, Landier F 1994 Growth of short normal children in puberty treated for 3 years with growth hormone alone or in association with gonadotropin-releasing hormone agonist. *Horm Res* 41:177–184
- Saggese G, Pasquino AM, Bertelloni S, Baroncelli GI, Battini R, Pucarelli I, Segni M, Franchi G 1995 Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. *Acta Paediatr* 84:299–304
- Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frolich M, Oostdijk W, Wit JM 2001 A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. *J Clin Endocrinol Metab* 86:2969–2975
- Visser-van Balen H, Geenen R, Moerbeek M, Stroop R, Kamp GA, Huisman J, Wit JM, Sinnema G 2005 Psychosocial functioning of adolescents with idiopathic short stature or persistent short stature born small for gestational age during three years of combined growth hormone and gonadotropin-releasing hormone agonist treatment. *Horm Res* 64:77–87
- Visser-van Balen H, Geenen R, Kamp GA, Huisman J, Wit JM, Sinnema G 2005 Motives for choosing growth-enhancing hormone treatment in adolescents with idiopathic short stature: a questionnaire and structured interview study. *BMC Pediatr* 5:15
- Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM 2000 Continuing positive secular growth change in The Netherlands 1955–1997. *Pediatr Res* 47:316–323
- Bayley N, Pinneau SR 1952 Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. *J Pediatr* 40:423–441
- Gerver WMJ, De Bruin R 1996 Paediatric morphometrics: a reference manual. Utrecht, The Netherlands: Bunge
- Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. *J Pediatr* 74:901–910
- Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston Jr CC, Lindsay RL 1995 Proximal femur bone mineral levels of US adults. *Osteoporos Int* 5:389–409
- Kroger H, Vainio P, Nieminen J, Kotaniemi A 1995 Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. *Bone* 17:157–159
- Wit JM, Boersma B, de Muinck Keizer-Schrama SM, Nienhuis HE, Oostdijk W, Otten BJ, Delemarre-van de Waal HA, Reeser M, Waelkens JJ, Rikken B 1995 Long-term results of growth hormone therapy in children with short stature, subnormal growth rate and normal growth hormone response to secretagogues. Dutch Growth Hormone Working Group. *Clin Endocrinol (Oxf)* 42:365–372
- Saggese G, Cesaretti G, Barsanti S, Rossi A 1995 Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls. *J Pediatr* 126:468–473
- Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzalan A, Laron Z 1997 Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. *Horm Res* 47:54–61
- Ranke MB 1996 Towards a consensus on the definition of idiopathic short stature. *Horm Res* 45(Suppl 2):64–66
- Wit JM 1999 Growth hormone treatment of idiopathic short stature in KIGS. In: Ranke MB, Wilton P, eds. *Growth hormone therapy—10 years' experience*. Heidelberg: Johann Ambrosius Barth Verlag; 225–243
- Crowe BJ, Rekers-Mombarg LT, Robling K, Wolka AM, Cutler Jr GB, Wit JM; European Idiopathic Short Stature Group 2006 Effect of growth hormone dose on bone maturation and puberty in children with idiopathic short stature. *J Clin Endocrinol Metab* 91:169–175

31. Palmert MR, Mansfield MJ, Crowley Jr WF, Crigler Jr JF, Crawford JD, Boepple PA 1999 Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. *J Clin Endocrinol Metab* 84:4480–4488
32. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler Jr GB 2003 Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. *N Engl J Med* 348:908–917
33. Kapteijns-van Kordelaar S, Noordam K, Otten B, van den BJ 2003 Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature. *Eur J Pediatr* 162:776–780
34. Van der Sluis I, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM 2002 Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. *J Clin Endocrinol Metab* 87:506–512
35. Finkelstein JS, Neer RM, Biller BM, Crawford JD, Klibanski A 1992 Osteopenia in men with a history of delayed puberty. *N Engl J Med* 326:600–604
36. Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 312:1254–1259
37. Castro J, Lazaro L, Pons F, Halperin I, Toro J 2001 Adolescent anorexia nervosa: the catch-up effect in bone mineral density after recovery. *J Am Acad Child Adolesc Psychiatry* 40:1215–1221
38. Fredericson M, Kent K 2005 Normalization of bone density in a previously amenorrheic runner with osteoporosis. *Med Sci Sports Exerc* 37:1481–1486

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

OCTOBER 9–11, 2007—San Miguel Island, Azores
8th Workshop on Resistance to Thyroid Hormone and Action

A forum for the presentation and discussion of the most recent basic and clinical achievements related to Resistance to Thyroid Hormone and Action

Ponta Delgada, San Miguel, Azores/Portugal
 Tel: +351-296209430
 Fax: +351-296209448
 E-mail: Joao_Anselmo@SAPO.pt
 Website: www.8thIWRTH.org